Lu, fluvoxamine meta analysis: 31% lower hospitalization [p=0.02] and 41% fewer combined hospitalization/ER visits [p=0.0004] https://c19p.org/lu2
copied to clipboard
Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: A systematic review and meta-analysis
et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.10.010
Systematic review and meta analysis of 4 fluvoxamine outpatient trials, showing lower hospitalization with treatment.Currently there are
12 fluvoxamine
for COVID-19 studies, showing 40% [-13‑68%] lower mortality, 22% [-28‑53%] lower ventilation, 33% [4‑53%] lower hospitalization, and 28% [18‑37%] lower cases.
|
risk of hospitalization, 31.0% lower, OR 0.69, p = 0.02, RR approximated with OR.
|
|
risk of hospitalization/ER, 41.0% lower, OR 0.59, p < 0.001, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Lu et al., 13 Oct 2022, peer-reviewed, 5 authors.
Contact:
dtmed141@gmail.com.
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.